BNTC
BENITEC BIOPHARMA INC.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q4 2024(8Q snapshot) | 6Q | $0.00 | — | — |
| Millennium Management re-entered | Q2 2025(8Q snapshot) | 4Q | $0.00 | — | — |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Benitec Biopharma Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 28, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-245918May 28, 2026
- Form 40001012975-26-000082Jan 26, 2026
- Form 40000899140-25-001479Dec 29, 2025
- Form 40000899140-25-001459Dec 22, 2025
- Form 40001012975-25-000851Dec 3, 2025
- Form 40001012975-25-000850Dec 3, 2025
- Form 40001012975-25-000849Dec 3, 2025
- Form 40001012975-25-000848Dec 3, 2025
- Form 40001012975-25-000847Dec 3, 2025
- Form 40001012975-25-000813Nov 20, 2025
- Form 40001012975-25-000812Nov 20, 2025
- Form 40001012975-25-000811Nov 20, 2025
- Form 40000899140-25-001256Nov 10, 2025
- Form 40001012975-25-000718Nov 7, 2025
- Form 40000899140-25-000486Apr 2, 2025
Fundamentals
XBRL · BENITEC BIOPHARMA INC.Annual figures sourced directly from BENITEC BIOPHARMA INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Benitec Biopharma Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 29, 2026
- 10-QQuarterly reportMay 14, 2026
- 8-KMaterial eventMay 14, 2026
- 10-K/AAnnual report (amended)Mar 20, 2026
- 8-KMaterial eventFeb 12, 2026
- 10-QQuarterly reportFeb 12, 2026
- S-3Registration (shelf)Jan 30, 2026
- 8-KMaterial eventDec 2, 2025
- 8-KMaterial eventNov 14, 2025
- 10-QQuarterly reportNov 14, 2025
- 8-KMaterial eventNov 7, 2025
- 8-KMaterial eventNov 3, 2025
- DEF 14AProxy statementOct 14, 2025
- S-3Registration (shelf)Sep 22, 2025
- 8-KMaterial eventSep 22, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q1 2026 | open | $0.00 | — | +0% |
| Millennium Management | Q1 2026 | open | $0.00 | — | +0% |
| Millennium Management | Q2 2025 | Q3 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q4 2024 | Q1 2025 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.